Today, Intercept Pharmaceuticals Inc. (ICPT) Receives Outperform Rating from Wedbush

Today, Intercept Pharmaceuticals Inc. (ICPT) Receives Outperform Rating from Wedbush

Wedbush restated their outperform rating on shares of Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) in a research report released on Saturday morning. Wedbush currently has a $224.00 target price on the biopharmaceutical company’s stock.

Several other equities analysts have also issued reports on the company. Needham & Company LLC reaffirmed a buy rating and issued a $350.00 target price on shares of Intercept Pharmaceuticals in a report on Friday, November 18th. FBR & Co reaffirmed a neutral rating on shares of Intercept Pharmaceuticals in a report on Friday, November 18th. Cowen and Company reaffirmed a buy rating on shares of Intercept Pharmaceuticals in a report on Tuesday, November 15th. Robert W. Baird reaffirmed an outperform rating and issued a $332.00 target price on shares of Intercept Pharmaceuticals in a report on Monday, November 7th. Finally, JMP Securities reiterated a buy rating on shares of Intercept Pharmaceuticals in a research note on Sunday, November 6th. Five research analysts have rated the stock with a sell rating, four have assigned a hold rating and eleven have given a buy rating to the stock. The company presently has an average rating of Hold and an average target price of $177.07.

Intercept Pharmaceuticals (NASDAQ:ICPT) traded up 1.37% during trading on Friday, reaching $115.84. The company’s stock had a trading volume of 207,545 shares. Intercept Pharmaceuticals has a 12 month low of $89.76 and a 12 month high of $186.87. The company’s market cap is $2.87 billion. The stock’s 50 day moving average is $124.14 and its 200 day moving average is $145.79.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($3.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.82) by $0.23. The company earned $4.70 million during the quarter, compared to analyst estimates of $4.77 million. Intercept Pharmaceuticals had a negative return on equity of 66.97% and a negative net margin of 3,287.95%. Intercept Pharmaceuticals’s quarterly revenue was up 1051.1% on a year-over-year basis. During the same period in the prior year, the company posted ($2.10) earnings per share. On average, equities analysts expect that Intercept Pharmaceuticals will post ($15.63) EPS for the current fiscal year.

In other news, insider Lisa Bright sold 155 shares of the firm’s stock in a transaction dated Monday, October 3rd. The stock was sold at an average price of $163.20, for a total transaction of $25,296.00. Following the transaction, the insider now directly owns 18,305 shares of the company’s stock, valued at $2,987,376. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Mark Pruzanski sold 35,000 shares of the firm’s stock in a transaction dated Tuesday, September 20th. The shares were sold at an average price of $165.00, for a total value of $5,775,000.00. Following the transaction, the chief executive officer now directly owns 579,314 shares in the company, valued at $95,586,810. The disclosure for this sale can be found here. Insiders own 9.20% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD boosted its position in shares of Intercept Pharmaceuticals by 381.5% in the third quarter. Price T Rowe Associates Inc. MD now owns 109,716 shares of the biopharmaceutical company’s stock worth $18,058,000 after buying an additional 86,931 shares during the period. Chartwell Investment Partners LLC bought a new position in shares of Intercept Pharmaceuticals during the third quarter worth about $10,181,000. Marco Investment Management LLC bought a new position in shares of Intercept Pharmaceuticals during the third quarter worth about $247,000. Opus Point Partners Management LLC bought a new position in shares of Intercept Pharmaceuticals during the third quarter worth about $215,000. Finally, Virtus ETF Advisers LLC boosted its position in shares of Intercept Pharmaceuticals by 14.4% in the third quarter. Virtus ETF Advisers LLC now owns 4,378 shares of the biopharmaceutical company’s stock worth $721,000 after buying an additional 552 shares during the period. 81.54% of the stock is currently owned by hedge funds and other institutional investors.

Intercept Pharmaceuticals Company Profile

Related posts

Leave a Comment